Patients with provoked venous thromboembolism caused by transient risk factors can generally stop anticoagulation after 3 months of treatment. For patients with unprovoked venous thromboembolism, for which the risk of recurrence is as high as 40% at 5 years, 1 it may be appropriate to consider a longer course of therapy. However, deciding how to balance the risks and benefits of extended anticoagulation is difficult. Warfarin has greater than 90% efficacy in preventing recurrences but carries an associated risk of major bleeding of 1 to 2% per year. 2 Warfarin is also a burdensome long-term treatment, with many food and drug interactions and the need for frequent monitoring.
Three studies reported in two articles in this issue of the Journal 3,4 examine the efficacy and safety of two new oral anticoagulants for extended treatment of unprovoked venous thromboembolism after initial anticoagulation therapy. In the double-blind RE-MEDY trial, 3 Schulman and colleagues randomly assigned 2866 patients designated by investigators to be at increased risk for recurrence of venous thromboembolism to receive dabigatran, a direct thrombin inhibitor, at dose of 150 mg twice daily, or warfarin (international normalized ratio, 2.0 to 3.0). Two other trials focused on patients whose treating physicians were uncertain about the need for continued anticoagulation. In the RE-SONATE trial, 3 1353 patients were randomly assigned to receive dabigatran (150 mg twice daily) or placebo for 6 months. In the AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) study 4 by Agnelli and colleagues, 2486 patients were randomly assigned to receive apixaban, a direct factor Xa inhibitor, at a dose of 2.5 mg twice daily or 5 mg twice daily, or placebo for 12 months.
Results of all three studies are summarized in Table 1 , along with results of a trial of extended treatment of venous thromboembolism with rivaroxaban, a direct factor Xa inhibitor. 5 Dabigatran met the investigators' noninferiority criteria for efficacy as compared with warfarin, with less major or clinically relevant nonmajor bleeding. Both drugs showed significantly greater efficacy than placebo. Bleeding was increased with dabigatran as compared with placebo. Surprisingly, the rates of recurrent venous thromboembolism were the same for both doses of apixaban, with bleeding rates that were not significantly different from the rate with placebo.
Dabigatran and apixaban have not been approved for short-term or extended treatment of venous thromboembolism, but rivaroxaban recently became the first new anticoagulant approved for this indication in the United States and Europe. Rivaroxaban was more effective than placebo for extended treatment of venous thromboembolism (82% reduction in relative risk), albeit with an increase in bleeding. 5 Recently published studies have also examined the role of aspirin in this context. 6, 7 In a pooled analysis of two similarly designed trials with carefully selected patient populations, 100 mg per day of aspirin reduced the risk of recurrent venous thromboembolism by 32%, with no increase in bleeding, as compared with placebo. Although aspirin may be safer than the newer agents, it appears to have less efficacy in reducing recurrent events.
With the potential for lower bleeding rates, easier administration, and similar efficacy, the new targeted anticoagulants are attractive alternatives to warfarin. The finding that a low prophylactic dose of apixaban has the same efficacy as the full therapeutic dose, with no increased risk of major bleeding, may tip the risk-to-benefit ratio in favor of extended treatment for this 
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patient population. The wide therapeutic window of this agent enables use of a lower dose that retains great efficacy with no or only a minimal increase in bleeding. This option is not possible with warfarin, for which a lower-intensity regimen has been shown to be less effective than standardintensity therapy but with a similar bleeding risk. 8 Despite the enticing results of these studies, questions and concerns remain. One might argue that direct comparison of these agents with one another, and with warfarin and aspirin, is needed to determine which confers the greatest protection from recurrent venous thromboembolism with the lowest rate of bleeding complications. The RE-MEDY trial is the only study to directly compare a new oral anticoagulant with warfarin in this context. Although dabigatran resulted in a 92% decrease in the rate of recurrent venous thromboembolism as compared with placebo in the RE-SONATE trial, the hazard ratio for recurrence as compared with warfarin was 1.44 in the RE-MEDY trial, with a 95% confidence interval (0.78 to 2.64) that just met the prespecified noninferiority margin of 2.85. The increase in the rate of acute coronary events with dabigatran as compared with warfarin, also reported previously, 9 requires further evaluation.
Current options for extended treatment after a first unprovoked venous thromboembolic event for patients deemed to be candidates for such therapy include aspirin, warfarin, and rivaroxaban, with other new anticoagulants likely to be approved soon. Deciding among these choices requires an individual assessment of risks of recurrence and bleeding. Patients with a perceived low-to-moderate risk of recurrence who desire some protection may benefit from the modest 32% risk reduction conferred by aspirin with little effect on lifestyle. Those who are believed to have a higher risk of recurrence, or more severe consequences of recurrence, will derive increased benefit from anticoagulation with warfarin or a new oral anticoagulant. Bleeding risk, however, must be considered. Both aspirin and warfarin have well-defined strategies to immediately reverse their hemostatic effects. Specific antidotes for the new oral anticoagulants are under development but not yet available. The AMPLIFY-EXT trial has shown that apixaban may be as safe as aspirin or even placebo.
The crux of using the new oral anticoagulants in clinical practice thus lies in the selection of appropriate patients. Patients in these studies were younger (average age, 56 years), with fewer coexisting diseases and a lower bleeding risk than patients typically seen in practice and no strong indications for continued anticoagulation (e.g., cancer, the antiphospholipid syndrome, or more than one event). Although it is hazardous to make comparisons across trials, the recurrence rates for the placebo groups in the dabigatran and apixaban trials are consistent with rates in previous trials involving patients with unprovoked venous thromboembolism. Improved riskstratification strategies are needed to identify patients who have the greatest risk of recurrence. These are the patients who stand to benefit most from extended anticoagulant treatment of a first unprovoked episode of venous thromboembolism.
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